Common genomic variants associated with variation in plasma lipoproteins in young aboriginal Canadians

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 17, Issue 6, 1997, Pages 1060-1066

  Hegele, Robert A ^a   Connelly, Philip W ^a   Hanley, Anthony J G ^b   Sun, Fang ^a   Harris, Stewart B ^c   Zinman, Bernard ^b  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b MOUNT SINAI HOSPITAL   (Canada)

^c UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

Apolipoproteins; Fatty acid binding protein; Hyperlipidemia; Paraoxonase; Polygenic traits; Small effects

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ARYLESTERASE; FATTY ACID BINDING PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ABORIGINE; ADOLESCENT; ARTICLE; ATHEROSCLEROSIS; CANADA; CHILD; DISEASE PREDISPOSITION; FEMALE; GENOME; GENOTYPE; HUMAN; HYPERLIPIDEMIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 0030980340     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.17.6.1060     Document Type: Article

References (36)

1. PDAY Research Group. Natural history of aortic and coronary atherosclerotic lesions in youth: findings from the PDAY study. Arterioscler Thromb, 1993;13:1291-1298.
2. Kwiterovich PO Jr. Dyslipoproteinemia and other risk factors for atherosclerosis in children and adolescents. Atherosclerosis. 1994;108:555-571.
3. Strong JP. Natural history and risk factors for early human atherogenesis. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) research group. Clin Chem. 1995;41:134-138.
4. Tracy RE, Newman WP III, Wattigney WA, Berenson GS. Risk factors and atherosclerosis in youth autopsy findings of the Bogalusa Heart Study. Am J Med Sci. 1995;310:S37-S41.
5. Breslow JL. Genetic basis of lipoprotein disorders. J Clin Invest. 1989;84:373-380.
6. Mehrabian M, Lusis AJ. Genetic markers for atherosclerosis and related risk factors. In: Lusis AJ, Rotter JI, Sparkes RS, eds. Molecular Genetics of Coronary Artery Disease: Candidate Genes and Processes in Atherosclerosis. Basel, Switzerland: Karger; 1992:363-418.
7. Hegele RA. The pathogenesis of atherosclerosis. Clin Chim Acta. 1996;246:2I-38.
8. Sing CF, Davignon J. Role of apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. Am J Hum Genet. 1985;37:268-285.
9. Baier LJ, Sacchettini JC, Knowler WC, Eads J, Paolisso G, Tataranni PA, Mochizuki H, Bennett PH, Bogardus C, Prochazka M. An amino acid substitution in the human intestinal fatty acid binding protein is associated with increased fatty acid binding, increased fat oxidation and insulin resistance. J Clin Invest. 1995;95:1281-1287.
10. Mitchell BD, Kammerer CM, O'Connell P, Harrison CR, Manire M, Shipman P, Moyer MP, Stern MP, Frazier ML. Evidence for linkage of postchallenge insulin levels with intestinal fatty acid binding protein (FABP2) in Mexican-Americans. Diabetes. 1995;44:1046-1053.
11. Hegele RA, Brunt JH, Connelly PW. A polymorphism of the paraoxonase gene associated with variation in blood pressure in a genetic isolate. Arterioscler Tliromb Vase Biol. 1995;15:89-95.
12. Ruiz J, Blanche H, James RW, Blatter Garin M-C, Vaisse C, Charpentier G, Cohen N, Morabia A, Passa P, Froguel P. Gln-Argl92 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet. 1995;346:869-872.
13. Serrato M, Marrian AJ. A variant of the human paraoxonase/ arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J Clin Invest. 1995;96:3005-3008.
14. Humbert R, Adler DA, Disteche CM, Hassett C, Omiecinski CJ, Furlong CE. The molecular basis of the human serum plasma paraoxonase activity polymorphism. Nat Genet. 1993;3:73-76.
15. Rees A, Stocks J, Sharpe CR, Vella MA, Shoulders CC, Katz J, Jowett NI, Barelle FE, Galton DJ. Deoxyribonucleic acid polymorphism in the apolipoprotein A-I-C-III gene cluster: association with hypertriglyceridemia. J Clin Invest. 1985;76:1090-1095.
16. Tas S. Strong association of a single nucleotide substitution in the 3'untranslated region of the apoIipoprotein-C-III gene with common hypertriglyceridemia in Arabs. Clin Chem. 1989:35:256-259.
17. Zeng Q, bammerman M, Takada Y, Matsunaga A, Breslow JL, Sasaki J. An apolipoprotein CIII marker associated with hypertriglyceridemia in Caucasians also confers increased risk in a west Japanese population. Hum Hered. 1994;95:37I-375.
18. Li W, Dammerman MM, Smith JD, Metzger J, Breslow JL, Leff T. Common genetic variation in the promoter of the human apoCIII gene abolishes regulation by insulin and may contribute to hypertriglyceridemia. J Clin Invest. 1995;96:2601-2605.
19. Nunez C, Gallagher D, Russell-Aulet M, Heymsfield SB. Bioimpedance analysis of body fat composition: a new measurement approach. Int J Obes Relat Metab Disord. 1994;18:P498.
20. Kushner RF, Kunigk A, Alspaugh M, Andronis PT, Leiten CA, Schoeller DA. Validation of bioelectrical impedance analysis as a measurement of change in body composition in obesity. Am J Clin Nutr. 1990:52:219-223.
21. Hegele RA, Brunt JH, Connelly PW. A polymorphism of the angiotensinogen gene is associated with variation in blood pressure in a genetic isolate. Circulation. 1994;90:2207-2212.
22. Hegele RA, Evans AJ, Tu L, Ip G, Brunt JH, Connelly PW. A genegender interaction affecting lipoproteins in a genetic isolate. Arterioscler Thromb. 1994;14:671-678.
23. Hegele RA, Brunt JH, Connelly PW. Multiple genetic determinants of variation of plasma lipoproteins in a genetic isolate. Arterioscler Thromb Vase Dial. 1995;15:861-871.
24. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Him I. J Lipid Res. 1990:31:545-548.
25. SAS Institute Inc. SAS/STAT User's Guide, Version 6. Cary, NC: SAS Institute Inc; 1990.
26. de Knijff P, Johansen L, Rosseneu M, Frants RR, Jespersen J, Havekes LM. Lipoprotein profile of a Greenland Inuit population: influence of anthropometrie variables, apoE and A4 polymorphism and lifestyle. Arlerioscler Thromb. 1992;12:1371-1379.
27. Blatter M-C, James RW, Messmer S, Barja F, Pometta D. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein K-45. Eur J Biochem. 1993;211: 871-879.
28. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 1991;286:152-154.
29. Saha N, Roy AC, Teo SH, Tay JSH, Ratnam SS. Influence of serum paraoxonase polymorphism on serum lipids and apolipoproteins. Clin Genet. 1991;40:277-282.
30. Kalow W. Interethnic variation of drug metabolism. Trends Pharmacol Sci. 1991;12:I02-107.
31. Lehtimäki T, Porkka K, Viikari J, Ehnholm C, Akerblom HK, Nikkari T. Apolipoprotein E phenotypes and serum lipids in newborns and 3-year-old children: the Cardiovascular Risk in Young Finns study. Pediatrics. 1994;94:489-493.
32. Jeunemaitre X, Soubrier F, Kotelevtsev YV, Lifton RP, Williams CS, Charru A, Hunt SC, Hopkins PN, Williams RR, Lalouel J-M, Corvol P. Molecular basis of human hypertension: role of angiotensinogen. Cell. 1992;71:169-180.
33. Fiddler T, Stevens JR. Killing the Shamen. Toronto, Ontario: Penumbra Press; 1985.
34. Pesonen E, Rapola J, Viikair J, Turtinen J, Akerblom HK. Altered serum lipid profile after systemic infection in children: risk factor for CHD? Eur Heart J. 1993;14:K7-K11.
35. Young TK, Moffatt MEK, O'Neil JD. Cardiovascular diseases in a Canadian arctic population. Am J Public Health. 1993;83: 881-887.
36. Trowell HC, Burkitt DP. Western Diseases: Their Emergence and Prevention. Cambridge, Mass: Harvard University Press; 1981.